



Cite this: *Org. Biomol. Chem.*, 2016, **14**, 3069

Synthesis, analysis and biological evaluation of novel indolquinonecryptolepine analogues as potential anti-tumour agents†

A. Le Gresley,* V. Gudivaka, S. Carrington, A. Sinclair and J. E. Brown

A small library of cryptolepine analogues were synthesised incorporating halogens and/or nitrogen containing side chains to optimise their interaction with the sugar–phosphate backbone of DNA to give improved binding, interfering with topoisomerase II hence enhancing cytotoxicity. Cell viability, DNA binding and Topoisomerase II inhibition is discussed for these compounds. Fluorescence microscopy was used to investigate the uptake of the synthesised cryptolepines into the nucleus. We report the synthesis and anti-cancer biological evaluation of nine novel cryptolepine analogues, which have greater cytotoxicity than the parent compound and are important lead compounds in the development of novel potent and selective indoloquinone anti-neoplastic agents.

Received 23rd November 2015,
Accepted 12th February 2016

DOI: 10.1039/c5ob02408k


www.rsc.org/obc

Introduction

Cryptolepine (**1**) has been known for some years to possess activity as an anticancer agent not only by intercalating into DNA but also by inhibiting the topoisomerase II. This has led to a number of derivatives being synthesised incorporating halogens at various ring positions.^{1–6} Comparison of anti-cancer activity of cryptolepines with chloro, bromo and iodo atoms at the 11 position showed considerable variation, with 11-bromo showing an improved cytotoxicity profile and the 11-chlorinated compound showing a reduction in the activity compared to the parent compound in the tested cell lines. Of those synthesised, 7,11-dichlorocryptolepine (**2**) showed the highest cytotoxic activity against MAC15a (colon adenocarcinoma) cells with an IC₅₀ value of 14.4 ± 2.8 μM (after 1 hour exposure).^{7,8}

Whilst the literature is generally in agreement that cryptolepines are an interesting target for anti-cancer research, the mode of action is still not that well understood.⁹ For example, it is observed that the cytotoxicity of cryptolepine is linked to its ability to inhibit the topoisomerase II enzyme so it would be expected that bromo and iodo compounds would show greater topoisomerase II inhibition owing to their increased lipophilicity. Topoisomerase II assay results of these 11-halogenated compounds showed they are responsible for greater inhibition compared to the parent molecule **1**, but surprisingly the 11-chloro derivative showed the highest topoisomerase II inhibition despite its lower *in vitro* cytotoxicity.^{10–12} It was hypothesised that this

could be due to the changes in drug–DNA interactions or drug uptake based on the structure and size of the molecule.¹³



Within this manuscript, we report the synthesis of novel cryptolepineaminoalkyl- and amidoalkyl-derivatives along with halogenated cryptolepines, including 11-iodocryptolepine. These compounds were screened for anti-cancer activity *in vitro* against cell lines MCF-7, A549 and DLD-1 using doxorubicin as positive control, data was also obtained pertaining to rates of cellular uptake and cellular localisation studies. The previously unreported biophysical and *in vitro* testing of halogenated cryptolepines and novel derivatives are discussed in an effort to clarify structure activity relationship and address the inconsistencies *vis* mode of action within the literature.

Materials and methods

Synthetic chemistry

The synthetic techniques used in the synthesis of the chosen targets are reasonably well known and details of key coupling

School of Life, Chemical and Pharmaceutical Sciences, SEC Faculty, Kingston University, Kingston-upon-Thames, KT1 2EE, UK. E-mail: a.legresley@kingston.ac.uk
† Electronic supplementary information (ESI) available: Synthetic details and spectroscopic data. See DOI: 10.1039/c5ob02408k



and quaternisation reactions are given in more detail under general procedures. Full spectroscopic data and detailed methodology is provided in the ESI.† Scheme 1 indicates the varied routes taken to achieve the synthesis of a series of amido, amino and halo-derivatised cryptolepines.

Instrumentation

NMR spectra were recorded on Bruker Avance III 400 two-channel FT-NMR spectrometer (AV400). It is equipped with a 5 mm BBFO+ probe (broadband multinuclear, auto-tune, with Z-gradients). Spectra were recorded using TopSpin 3.0 pl4, © 2010 Bruker BioSpin, control and processing software and Icon NMR 4.5.1 Build 51 for TopSpin 3.0 automation software. Mass spectra of compounds were obtained using a Waters LCT-TOF-MS instrument using ESI selective mass detector and Agilent 5973 GC-MS. High resolution mass spectra of compounds were obtained from Medac labs, UK (BS EN ISO9001:2008) using Waters LCT Premier (ES-ToF)/Acquity i-Class mass spectrometer. Infrared spectra were recorded on Thermo Scientific™ Nicolet™ iS™5 FT-IR Spectrometer. Melting points were measured using Gallenkamp digital melting-point apparatus 5A 6797. Up to 350 °C (division: 0.1 °C. 220 V) unless otherwise stated, all the chemicals used in the synthesis were purchased from Sigma Aldrich, UK.

General procedures

Specific details of intermediate synthesis and spectroscopic data are found in ESI.† The below general procedures outline the final synthetic steps for the cryptolepine derivatives as indicated in Table 1.

General procedure for quaternisation A (4d, 5a–5c). Under dry conditions, 10*H*-indolo[3,2-*b*]quinoline (or its 11-halo derivative) and methyl/ethyl triflate were stirred in anhydrous toluene for 24 hours at room temperature. The reaction mixture was poured in diethyl ether and the resulting yellow precipitate was collected by filtration. Aqueous ammonia solution (3.3% v/v) was added to the precipitate and the mixture was stirred to convert the product to its free base form. Then the mixture was extracted using chloroform (4 × 75 ml). The collected organic layers were combined and evaporated *in vacuo* to give the crude product which was then purified by column chromatography on silica gel by using DCM: methanol:NH₄OH (5:1:0.1) as the eluent. Finally the free base was converted to its hydrochloride salt by neutralising with 0.1 M methanolic hydrochloric acid (5 ml) and then solution was evaporated *in vacuo* to give the desired *N*5-methyl or *N*5-ethyl cryptolepine derivative, as a yellow coloured solid.

General procedure for quaternisation B (1 & 4a–4c). Methyl iodide was added drop wise to a solution of sulfolane and 11-bromo-10*H*-indolo[3,2-*b*]quinoline and stirred under nitrogen for 16 hours at 50 °C. The reaction mixture was cooled to room temperature then ether (25 ml) and methanol (5 ml) were added to induce precipitation. Diethyl ether (25 ml) was added and then the mixture was filtered and the solid was dried *in vacuo*. The solid was mixed with aqueous sodium carbonate solution (10% w/v, 30 ml) followed by extraction with

chloroform (4 × 30 ml). The organic layers were combined and dried using magnesium sulfate and filtered. The solvent was removed *in vacuo* to concentrate the solution which was then treated with a solution of methanolic hydrochloric acid (0.1% v/v) drop wise to give hydrochloride salt of cryptolepine as a bright yellow coloured solid.

General procedure for amide coupling reaction C (5a–5c). To finely ground 10*H*-indolo[3,2-*b*]quinoline-11-carboxylic acid, dichloromethane and DMF were added and the mixture was stirred for 15 min. NEt₃ was added drop wise under continuous stirring before adding COMU to the solution, which was then stirred for 10 min. The desired amine was added drop wise and the reaction mixture was stirred for 16 hours at room temperature.

The reaction mixture was added to ethyl acetate (100 ml) and extracted with aqueous 1 M HCl solution (2 × 30 ml) and aqueous 1 M sodium bicarbonate solution (2 × 30 ml). Then the organic layers were collected and dried using magnesium sulphate and evaporated *in vacuo* to give the crude quindoline amide, which was purified by column chromatography over silica gel using ethyl acetate: hexane (1:1) and dried *in vacuo* to give desired alkylamidoquindoline.


General procedure for 11-chloro substitution D (3a–3e). To a solution of 11-chloro-5-methyl(or ethyl)-10*H*-indolo[3,2-*b*]quinolin-5-ium chloride (4c) in ethyl acetate, the desired amine was added and the contents of the flask were heated to reflux for 16 hours. The reaction mixture was cooled down to room temperature and the precipitate was collected by filtration and washed with diethyl ether and dried *in vacuo* to give yellow coloured crystals.

Biological methods

General. RPMI culture medium, DMEM culture medium, Foetal bovine se-rum (FBS), penicillin–streptomycin solution (10 000 U per mL penicillin, 10 mg per mL streptomycin), L-glutamine (200 mM), Trypsin, Trypan blue solution, MTT, Doxorubicin, Dimethyl sulfoxide (DMSO) (biological grade) were obtained from Sigma Aldrich, UK. 96 well culture plates, T75 ml flasks, and pipettes were purchased from Fischer Scientific, UK. Plate reader used to scan the 96 well plates was Lab-tech LT-4000. The Incubator used to grow the cells was from Thermo Scientific, UK. The human cell lines, MCF-7, A549 and DLD-1 cells were kindly provided by the Institute of Cancer Therapeutics, Bradford University, Bradford, UK.

Cell line culturing. The three cell lines were cultured in RPMI medium supplemented with 10% heat inactivated foetal bovine serum, 10 000 U per mL penicillin, 10 mg per mL streptomycin and 200 mM L-glutamine. Cells were grown in 95% humidified air mixed with 5% carbon dioxide at a fixed temperature of 37 °C. Exhausted growth medium was replaced with fresh growth medium every two days. When the cells reached 90% confluence, they were sub-cultured. Firstly, in a laminar flow chamber, the media was removed and the cell were washed with 15 ml of PBS and then 2.5 ml of trypsin-EDTA solution was added then incubated for 5–7 min to allow the cell splitting to takes place. Then cells were observed under a





Scheme 1 Synthetic route for the cryptolepine derivatives. (a) POBr_3 , PBr_3 , 16 h, reflux (b) POCl_3 , PCl_5 , 4 h reflux. General procedures are given as Proc. A–D and are discussed in more depth in the methods section: (A) methyl/ethyl triflate, 34 h, RT (B) MeI, sulfolane 16 h RT (C) COMU, Et_3N , DCM 16 h RT (D) EtOAc, amine, 16 h, reflux.



Table 1 Yields for synthesised halo-, alkylamino- and alkylamido analogues

Compound	Yield (%)
1	N/A
3a	61 ^b
3b	68 ^b
3c	67 ^b
3d	23 ^b
3e	35 ^{a,b}
4a	11
4b	65
4c	56
4d	74 ^a
5a	83 ^b
5b	91 ^b
5c	12 ^b

^a Denotes the ethyl quaternary ammonium salt rather than methyl, which is the case for the rest. Details of the synthetic methodology and supporting spectroscopic data are available in ESI. ^b Denotes the synthesis compounds first reported in this paper.

light microscope (20×) to check if they were detached. If needed they were tapped gently to detach from each other. Fresh growth medium (10 ml) was added and the suspension was aspirated using a pasture pipette. For further culturing 2 ml of that suspension was taken and added to 20 ml of fresh growth medium in a T75 flask and incubated.

Growth curves. Growth curves were plotted on three cell lines MCF7, A549 and DLD-1 to observe the growth characteristics of the cells. The MTT assay was used to determine the growth of the cells over the course of time. Cells were seeded in a series at varying densities (500, 1000, 2000, 4000, 8000, 16 000, 32 000 and 64 000) at a final volume of 200 µL and incubated for 96 hours. Two-hundred microliters of the growth medium without cells served as the blank for the assay. Following incubation, the medium was removed and 25 µL of the MTT reagent (concentration) was added to each well and incubated for 3 hours. The purple formazan crystals were solubilised with 100 µL of DMSO and gentle shaking. Plates were then left in the dark for an hour and were then scanned at 570 nm using a plate reader. A graph was plotted with the average absorbance on the Y-axis and cell count on the X-axis. This was replicated thrice on the same plate in three rows.

MTT/ATP assay. DMSO (biological grade) was used to dissolve cryptolepine and its analogues to reach a drug concentration of 10 mM (stock solution A). Serial dilutions of stock solution A were prepared (100 µM, 10 µM, 1 µM, 0.1 µM, 0.01 µM and 0.001 µM) at a final volume of 10 mL. All of the drug solutions made were stored at -20 °C and thawed when required for the MTT assay experiment. The final concentration of DMSO in the working stocks did not exceed 0.1% v/v. Twenty thousand cells were seeded per well and treatment applied after 24 hours. After X hours of treatment, the medium was removed (including control cell-free wells) and the MTT assay carried out as described in the previous section.

After MTT treatment purple coloured crystals were observed under the microscope then medium from each well was care-

fully removed and 100 µL of DMSO were added to dissolve the precipitate and the plate was left in the dark for an hour. The obtained raw data was then analysed using MS-Excel (2010) software and the IC₅₀ values were calculated using the Graph-Pad Prism software (version 6.0).

Topoisomerase II inhibition studies. A topoisomerase II assay kit was purchased from Topogen, Florida, USA (Topogen, 2005) – kDNA, decatenated kDNA marker, Linear kDNA marker, gel loading buffer, protein kinase buffer A: mixture of Tris-HCl (pH-8) (0.5 M), NaCl (1.50 M), MgCl₂ (100 mM), dithiothreitol (5 mM), bovine serum albumin (BSA) (300 µg mL⁻¹). Buffer B: 20 mM ATP in water: drugs: cryptolepine and its analogues Eppendorf tubes, Micro pipettes and pipette tips, A grade glassware. 1% Agarose gels were prepared (0.75 g agarose in 75 mL tris buffer) and ethidium bromide (0.5 µg mL⁻¹) added to the solution. The solution was allowed to solidify at room temperature for an hour prior to loading. Running Buffer (TAE buffer): 50× concentration: tris base (242 g), glacial acetic acid (57.1 mL) and of 0.5 M EDTA (100 mL). Diluted to 1× cryptolepine and its analogues were initially dissolved in DMSO and then diluted to reach the desired concentration. Serial dilutions were carried out to produce a concentration range of 100 µM to 0.01 µM. The maximum DMSO concentration did not exceed 0.1% v/v. Buffer (2 µL complete reaction buffer = buffer A + buffer B in 1 : 1 ratio), kDNA (0.25 µg mL⁻¹, 1 µL), bovine serum albumin (30 µg mL⁻¹, 1 µL), distilled water (to make up to 20 µL), drug to be tested in desired concentration (1 µL) were pipetted out to a Eppendorf tube and incubated for 30 minutes at 37 °C.

The reaction was then stopped by adding 4 µL of stopping buffer and 2 µL of protein kinase. The mixture was then incubated for digestion for 30 minutes. The reaction products were then loaded on to the ethidium bromide-agarose gel and electrophoresis was carried out at 65 V for 2.5 hours in TAE buffer. After the separation, the gel was visualised under UV illumination.

Fluorescence microscopy. Using BD-Falcon 8 chambered culture slides, A549 cells were grown in RPMI medium without any indicator. A cell seeding density of 4000 cells per well was determined as optimum and was used for fluorescence microscopy. After 17 hours of incubation, the chamber slides were taken out and the medium was carefully removed and loaded with the desired concentration of the drug solution in RPMI medium and further incubated for 1 hour. Cells were gently washed with PBS (37 °C), stained with DAPI nuclear stain (5 mg mL⁻¹) and shielded using a fluoro-shield solution to protect from photo bleaching. A cover slip was placed on the slide ensuring no air bubbles formed and sealed. Drug localisation in the cells was observed under the microscope at 40× magnification. Firstly, images were captured under normal light at 40× magnification and then using fluorescent filters, the blue cell nuclei were captured. By changing the filter to green again the whole cells were observed to see the drug localisation. Finally both the nuclei and whole cell images were overlaid using the Leica microscopy imaging software.

In vitro drug-uptake studies. Cryptolepine and its derivatives were dissolved in methanol and the solutions were



scanned using a UV spectrophotometer and the λ -max was recorded. Using these wavelength readings, samples were excited using a fluorescent spectrophotometer to record their emission wavelengths.

Cells were grown in a 96 well plate for 24 hours in phenol red-free RPMI medium at a seeding density of 20 000 cells per well. Seven rows of 3 columns ($7 \times 3 = 21$ wells) were loaded with cell suspension for incubation. Twenty four hours post incubation, media from the first row of the cells was removed and loaded with 100 μ L of drug solution (solvent = media) with a concentration of 10 μ M and the plate was placed back in to the incubator. After 30 min. the plate was removed from the incubator and the media from the second row was removed and loaded with 100 μ L of drug solution (10 μ M). The same procedure was repeated for the remainder of the rows every 30 minutes, leaving the last row with no treatment (blank). After the treatments were complete, the drug solutions were gently removed and 100 μ L of DMSO was added to the wells and shaken gently for 30 minutes. The positive control wells were filled with 100 μ L of 10 μ M drug solution.

Cells were lysed using Triton X-100 (a non-ionic surfactant which increases the cell permeation) and the drug was extracted using methanol. The plate was then scanned using a fluorescence plate reader measuring the intensity of the fluorescence from each well (25 scans for each well). The 8th was filled with 10 μ M drug solution, which served as a positive control for the experiment. Using a positive control (100% drug solution), data was analysed and compared to generate the report of percentage drug uploaded into the cells over the period of three hours.

Drug-DNA binding assay. Duplex DNA (DS26) and quadruplex DNA (AG23) oligonucleotides were purchased from Eurogenetic, Belgium. Fluorometric titrations were performed on Varian-Cary Eclipse fluorescence spectrometer (scans at 24 000 nm min^{-1} , radiation source is Xenon flash lamp with room light immunity) with carry eclipse spectrophotometric software. Sodium cacodylate was purchased from Sigma Aldrich, UK. Made using 0.2 M sodium cacodylate and 0.2 M HCl thiazole orange was purchased from Sigma Aldrich, UK. Cacodylate buffer was made by dissolving sodium cacodylate crystals (42.8 g) in distilled water (1 L) and the pH was adjusted to 7.3 using aqueous HCl solution (0.2 M). The G-quadruplexes were made by heating the 22AG nucleotide in the cacodylate buffer (10 mM, pH 7.3), 100 mM KCl at 90 $^{\circ}$ C for five minutes and then the solution was cooled in ice to form G-quadruplexes by intermolecular folding. This duplex nucleotide sequence was made by heating DS26 in the cacodylate buffer (10 mM, pH 7.3), 100 mM KCl at 90 $^{\circ}$ C for five minutes and then slowly cooling over a period of 6 hours. Once these DNA solutions were made, the concentrations were measured using the UV-VIS spectrophotometer at 260 nm using their extinction coefficient values.

Cacodylate buffer containing 100 mM of KCl was used for all the dilutions to get desired concentrations. In a 3 mL capacity cuvette, 1 mL of thiazole orange solution and 1 mL of DS26 solution were pipetted and then the volume was adjusted to 3 mL using the blank buffer. The fluorescence was measured

using the fluorimeter. This served as a control for the titration. For the ligand binding experiments, first 1 mL of thiazole orange and 1 mL of DS26 solution were put into a cuvette and then the total concentration of ligand was made to 0.375 μ M by adding the desired ligand and the volume was made up using the cacodylate buffer. The solution was allowed to equilibrate for 3 min and then the fluorescence intensity was measured.

The same was repeated for each fluorometric titration by increasing the concentration of ligand to 0.75 μ M, 1.5 μ M, 3.0 μ M, 4.5 μ M, 7.5 μ M in the cell and keeping the total volume of the cell constant at 3 mL. The same procedure was carried out for the G-quadruplex sequence with the only difference being the concentration of thiazole orange used which was compared to DS26. The reason for this is that quadruplex sequence has a smaller number of binding sites compared to the duplex sequence of DS26. During the titration, depending on the activity of the ligand, a gradual fall in the fluorescence was seen as the concentration of the ligand increased.

All the concentrations were recorded using the Carry Eclipse software and the integral graphs were plotted for each ligand concentration measured. The decrease in percentage of fluorescence intensity was measured for each ligand concentration and hence the binding efficiency of the ligand was interpreted.

Results – synthesis

In addition to probing the halocryptolepine activity, alkyl-amino side chains were attached to increase lipophilicity and improve overall drug uptake. For the same reason alkylamino side chains with different lengths were selected to see if there is any correlation between side chain length and the drug uptake in the cell lines *in vitro*.

11-Chlorocryptolepine served as the key intermediate to make the derivatives with amino linkages at 11-position *via* nucleophilic substitution (see general procedure D). In the derivatives with amino linkages, it is unlikely that the secondary amine present on the side chain can be protonated at physiological pH but it is possible that the positive charge arising from the pyridinium nitrogen (Fig. 1) can resonate to transfer the positive charge to the side chain. This structure can potentially better interact with the negatively charged phosphate backbone of DNA which should ultimately lead to improved binding interactions.

Unlike derivatives with amino linkages, in the derivatives with amido linkages, the positive charge will not be able to move to the aromatic ring (Fig. 1). So these compounds were made to see how having an amide bond between side chains and the aromatic system of cryptolepine will affect the cytotoxicity and the *in vitro* drug uptake in cancer cells.

Results – *in vitro* and biophysical testing

Three different cancer cell lines: MCF-7 (breast cancer) A549 (lung cancer) DLD-1 (colon cancer) were used to test the anti-






Fig. 1 Possible resonance structure for 11-aminocryptolepine derivatives.

cancer activity of the synthesised cryptolepine analogues. In addition to ease of culture and laboratory maintenance, choosing these cell lines make it possible to compare the results with previous literature.^{14a-c} All three cell lines incubated with cryptolepine **1** for 96 hours, showed anti-proliferative activity. The greatest activity was against A459 cells with an IC_{50} value of $0.47 \pm 0.12 \mu\text{M}$ compared to MCF-7 and DLD-1 cells on which it gave IC_{50} values of $5.9 \pm 0.69 \mu\text{M}$ and $1.25 \pm 0.77 \mu\text{M}$ respectively (Table 2), which are in agreement with similar experiments carried out by Gokcek *et al.* on A-549 and DLD-1 cells and reported IC_{50} values of $0.55 \pm 0.05 \mu\text{M}$ and $1.44 \pm 0.002 \mu\text{M}$.¹⁵ From the dose response curve it is observed that no significant activity was seen until a $0.10 \mu\text{M}$ concentration of cryptolepine was applied. After that there was a gradual downward trend until $1.00 \mu\text{M}$. Once the concentration reached $10 \mu\text{M}$, the percentage cell survival was essentially zero.

Cell viability

After exposing cells to $1 \mu\text{M}$ or higher It was observed under the microscope that cells started changing morphology. As the concentration increased, more cells were lysed and more cell debris was observed. Compounds **3b** and **3c** showed a higher level of activity compared to **3a** suggesting that having an alkyl-amino side chain is structurally significant. In particular, compound **3b** showed 10 times greater activity than the parent compound **1** with an IC_{50} value of $0.63 \pm 0.51 \mu\text{M}$. Interestingly **3c** derivative showed a greater activity than **3b** for A549 and DLD-1 cells with IC_{50} values of $0.83 \pm 0.28 \mu\text{M}$ and 2.4 ± 0.96 respectively (Fig. 2).

Unsurprisingly, these results indicate the dependence of the activity in the specific cell line being tested, however the results of testing against cancer cell lines suggest that alkyl-amino amino side chains may be useful in forming electro-

Table 2 *In vitro* and biophysical test results for the synthesised derivatives **3a–3e**, **4a–4d** and **5a–5c** for comparison with cryptolepine **1**. MIC for topoisomerase II inhibition refers to the minimum inhibitory concentration as per Bonjean *et al.*¹⁰

Compound	A549 cells IC_{50} (μM)	MCF-7 cells IC_{50} (μM)	DLD-1 cells IC_{50} (μM)	Topoisomerase II inhibition MIC (μM)	DS26 binding (K_d)	22AG binding (K_d)
1	0.47 ± 0.12	5.90 ± 0.69	1.25 ± 0.77	0.5	1.62 ± 0.62	2.45 ± 0.36
3a	20.38 ± 2.01	17.92 ± 2.31	37.05 ± 2.36	—	2.51 ± 0.33	39.81 ± 5.17
3b	1.05 ± 0.15	0.63 ± 0.51	2.85 ± 0.87	0.25	0.79 ± 0.37	5.01 ± 1.85
3c	0.83 ± 0.28	4.253 ± 1.88	2.4 ± 0.96	—	1.26 ± 0.26	6.31 ± 3.15
3d	10.41 ± 0.75	6.77 ± 2.03	12.23 ± 1.20	—	2.51 ± 0.58	3.98 ± 1.53
3e	12.58 ± 2.12	43.59 ± 4.72	26.73 ± 3.92	—	1.55 ± 0.55	26.92 ± 6.96
4a	5.16 ± 1.25	2.15 ± 0.41	3.35 ± 1.62	—	—	—
4b	0.28 ± 0.1	0.1 ± 0.02	0.34 ± 0.05	—	0.10 ± 0.06	0.32 ± 0.10
4c	42.83 ± 3.74	62.87 ± 2.71	81.58 ± 2.61	0.25	0.40 ± 0.20	0.63 ± 0.02
4d	15.24 ± 2.20	21.00 ± 3.62	31.84 ± 3.86	—	—	—
5a	42.64 ± 3.17	31.72 ± 2.56	75.01 ± 2.92	>100	—	—
5b	21.41 ± 1.76	7.26 ± 1.24	4.14 ± 0.89	—	2.00 ± 0.74	3.55 ± 1.04
5c	12.38 ± 2.16	9.15 ± 1.56	15.21 ± 3.23	—	—	—






Fig. 2 Dose–response curve for **1** against MCF 7 (–○–), A549 (□) and DLD-1 (△) cancer cell lines.

static interactions with the negatively charged DNA backbone.^{16,17} Addition of a hydrophilic motif as in the case of **3d** failed to improve upon the anticancer activity, however it was shown to still be superior to the more lipophilic **3b** derivative.

The derivative **3d** is actually similar to mitoxantrone and showed greatest activity on the breast cancer cells with an IC_{50} value of $6.77 \pm 2.03 \mu\text{M}$. This selectivity was also observed when Von Hoff and his team tested mitoxantrone on 20 different tumour cell lines, where greatest activity against breast cancer (MCF-7) cells compared to DLD-1 cells was observed.^{18a,19} The anti-proliferative activity shown by **4b** was most potent, with **4a** showing the second highest activity among all the halogenated compounds tested. The 11 halogenated analogues followed a downward trend of activity from 11-iodo to the 11-chloro derivative indicating the importance of a lipophilic group in the 11 position. The importance of halogen interactions has been reported by Sarwar *et al.* where the potential for encapsulation augments the role of halogen interactions, which are negligible in comparison with the bulk solvent interactions.^{18b}

This van der Waals interaction between iodine and amino hydrogens is important ($3.43 \pm 0.33 \text{ \AA}$) for optimal binding and selectivity of drug towards that particular DNA sequence.^{18a} A gradual decrease in the DNA-binding has been similarly observed from iodo to fluoro analogues of Calicheamicine. This could mean that the presence of Iodine atom at 11-position may have been involved in similar molecular interactions which were contributing for the DNA binding efficiency of **4b**.

Derivatives **5a–5c** showed comparatively less activity than the other sets. Amongst the amido-derivatives, **5c** showed the highest activity whereas the **5a** derivative showed lowest activity. Regardless of whether it is an amino derivative and an amido derivative, the isopropyl group reduced the activity significantly, possibly due to the steric hindrance imparted by the isopropyl functional group.

Amongst all the molecules synthesised, derivatives with 11-alkylamino linkages and 11-halogenated compounds showed comparatively greater activity than compounds having 11-amido side chains.

Topoisomerase II inhibition studies

Cryptolepine has been tested for topoisomerase II activity in the past using both of the methods outlined above and it has been proposed that cryptolepine acts as a topoisomerase II poison.^{20,21} A random derivative was selected from each set for Topoisomerase II testing. When cryptolepine **1** was tested for its topoisomerase II activity it gave a minimum inhibitory concentration value (MIC) of $0.5 \mu\text{M}$. The same result was reported by Bonjean and his team on supercoiled plasmid DNA obtained from *Escherichia coli*.¹⁰

Cryptolepine **3b** showed the highest topoisomerase II inhibition of the compounds tested and also the highest overall cytotoxicity. This continues to support the link between the two. The analogue **5a** gave much lower topoisomerase II activity than the parent compound; however the **4c** derivative failed to confirm this correlation between Topoisomerase II inhibition and cytotoxicity. The topoisomerase II activities obtained from both compounds **3b** and **4c** are significantly higher than that of the parent compound.

It is possible that the lack of correlation between Topoisomerase II inhibition and cytotoxicity may be due to differences in the pharmacokinetics profile of the compounds in so drug uptake was investigated.

Fluorescence microscopy

Fluorescence microscopy was used to investigate whether the derivatives were reaching the nucleus by crossing the cellular membrane and nuclear envelope. For this experiment A549 cells were selected by observing the morphology under a microscope. Though the cultured cells are in monolayers, MCF-7 and DLD-1 cells tend to form clusters in the culture plate whereas A549 cells are evenly spread. Out of the compounds scanned, **4a–4c** and **3b** emitted high enough fluorescence intensity to facilitate fluorescence microscopy. Derivative **3b** was selected as one of the most active and **4c** was included with view to identifying the reason for its low cytotoxicity despite high topoisomerase II activity. Fluorescence microscopic pictures were taken for both DAPI and the cryptolepine derivatives by exciting them at their respective excitation wavelengths and then overlaying them to identify co-localisation.^{22,23}

Co-localisation of DAPI and **3b** in the nucleus of A549 cells indicated that although **3b** was spread all over the cell, high concentrations are localised at nucleus, which was clearly seen in the pictures as more bright fluorescence was arising from the nucleus of the cell which is co-localised with DAPI (Fig. 3).

The same was observed with **4c** but the fluorescence intensity seemed to be lower than **3b** (Fig. 4). This is supported by similar experiments conducted by Redshaw *et al.* to see the cellular localisation of fluorescent zinc complexes using DAPI as a counterstain.²⁴

These drug localisation experiments only gave information about whether the drug is present in the nucleus or not. By measuring the amount of drug taken up by the cells after treatment for particular time will give quantitative information about the rate of drug uptake in the cells.






Fig. 3 Showing co-localisation of DAPI and drug in the nucleus of A549 cells. Magnification: 40 \times , green: **3b** (A), blue: DAPI nuclear dye (B), overlay of both **3b** and DAPI (C).

In vitro drug uptake studies

To carry out the drug uptake studies A549 cells were selected because, after drug treatment, they make evenly spread monolayers. MCF-7 and DLD-1 cells tend to form clusters in the culture plates this was observed under microscope while performing cytotoxicity assays. Based on the observed lack of cell expansion the images suggest apoptosis as the pathway and this is supported by the literature.²⁵

Drug uptake was determined using the method of Kunwar *et al.*²⁶ Fluorescence intensity was measured and compared using a positive control of the same drug solution and result was expressed as percentage drug uptake. Cryptolepine derivatives from each set were chosen at random. The amount of fluorescence exhibited by each drug can be different, so the same drug was taken as positive control (without any cells




Fig. 4 Showing co-localisation DAPI and drug in the nucleus of A549 cells. Magnification: 40 \times , green: 11-chloro cryptolepine, blue: DAPI nuclear dye, overlay of both drug and DAPI.

being present – 100%) percentage drug uptake was calculated. This percentage drug uptake was directly proportional to the amount of drug present in the cells.

Looking at the *in vitro* drug uptake results, **3b** was taken up into the cells more quickly than any other compounds tested reaching 40% within first 30 min after drug treatment, then it continued to rise up to 60% in 1.5 hours. After 1.5 hours percentage drug uptake started to decrease reaching to a 20% at 3 hours this could be due the oozing of cellular contents along with drug from ruptured cell membranes of dying cells. This high rapid percentage drug uptake into the cells may be the reason for high activity of **3b** (Fig. 5).

In the case of **4c**, the percentage drug uptake only reached 25% in the first 30 minutes and then increased to 40% after 2 hours then it started to decline and reached about 30% after three hours. This lower uptake rate might be the reason behind the lower cytotoxicity of **4c**. Another important issue in the drug uptake profile of this compound was that the intracellular concentration of **4c** did not fall as quickly as **3b**. This may be due to lower cytotoxicity of the **4c**.

11-Isopropylaminocryptolepine **3a** gave a poor uptake profile with a percentage uptake of 8% in the first thirty minutes which is 6 times lower compared to **3b** and approximately 4 times lower than the parent compound **1**. The maximum drug uptake for **3a** of 18% was seen at 2.5 hours which is 3 times lower than **3b**.

Drug-DNA binding

Since cryptolepines have the potential to act as an anticancer agent by intercalating into DNA, it was felt prudent to investigate binding efficiencies to see whether the novel derivatives showed improved binding with respect to **1**. The aim was also to better understand the mode of action to address the counterintuitive relationship between for example, the high topoisomerase II activity, yet low cytotoxicity for **4c**.

Fluorescence displacement assay was selected as method of choice for the current project for its robustness and the fact that we could use different types of DNA sequences (duplex, quadruplex) to test a group of random cryptolepine derivatives covering the different classes synthesised.

Using this fluorimetric titration assay, cryptolepine derivatives were tested for their selectivity and efficiency of DNA binding. This assay was done using two types of DNA sequences; one was a duplex-forming DNA (DS26) and the other was quadruplex-forming DNA (22AG).

22AG is an oligonucleotide which is similar to the human telomeric sequence. It is a repeat of the [5'-AG3(T2AG3)3-3'] which forms G quadruplex DNA. DS26 is a self-complementary DNA sequence 5'-CA2TCG2ATCGA2T2CGATC2GAT2G-3' which form a duplex DNA.²⁴ The gradual decrease in the fluorescence arising from displacement of thiazole orange from quadruplex and duplex DNA is used to profile the binding upon gradual increase of the ligand concentration.

Reference to Table 2 shows that the 11-halocryptolepines **4b** & **4c** had the best DNA binding overall with slightly more selectivity towards duplex DNA over G-quadruplex DNA. The






Fig. 5 Showing the rate of drug uptake of a range of cryptolepine derivatives in A549 cells.

11-iodo compound **4b** showed the highest DNA binding constant in both duplex and quadruplex sequences. This reinforces the cytotoxicity data as high cytotoxicity was shown by the 11-iodo compound **4b**. Interestingly the 11-chloro derivative **4c** showed better DNA binding efficiency than parent molecule despite having a poorer cytotoxicity profile.

The 11-alkylamino derivatives **3a–3e** showed better DNA binding than **1**, especially the molecules **3b** and **3c** with the 11-butylamino and pentylamino side chains. The same pattern of DNA binding for this class of cryptolepine derivatives was observed for the cytotoxicity data. The 11-isopropylamino derivative **3a** showed binding efficiency to G-quadruplex which is 16 times lower than its duplex DNA affinity. When compared to **1**, **3b** and **3c** derivatives showed higher binding efficiency to duplex DNA, implying that the compounds with 11-alkylamino side chains prefer duplex DNA over quadruplex DNA.

Even though derivative **3d** with the aminoalcohol side chain did not show particularly strong binding to duplex DNA, its quadruplex binding efficiency is considerably higher than

derivatives **3a–3c**. More importantly there is not much selectivity of **3d** for duplex or quadruplex DNA.

Derivative **5b** was selected from the 11-alkylamido class as it showed higher cytotoxicity compared to the other 11-alkyl amido derivatives. It showed less binding efficiency towards both duplex and quadruplex DNAs when compared to **1** but it showed better quadruplex binding than the 11-alkylamino derivatives implying that it prefers G-quadruplex structures than duplexes. Overall cryptolepines appear to bind preferentially to duplex DNA over G-quadruplex DNA, this may be because of its selectivity towards GC rich sequences present in the duplex DNA.²⁷

Conclusions

The purpose of this study was to attach halogens (Cl, Br and I) and amino/amido-alkyl side chains at the 11-position of cryptolepine and then investigate these molecules for anti-



cancer activity using established *in vitro* cytotoxicity assay and biophysical studies including DNA binding assays, topoisomerase II assays, fluorescence microscopy and quantitative drug uptake studies.

Of the novel derivatives synthesised the 11-aminoalkyl and 11-halo cryptolepines (**3a–3d** & **4a–4c** resp.) showed greater activity than those with 11-amido side chains (**5a–5c**). Overall, the 11-iodo **4b** and the 11-butylamino **3b** derivative showed the highest activity (Table 2). The reason for the enhanced cytotoxicity of **3b** could be the lipophilic alkyl side chain which may facilitate faster drug-uptake by the cells.

Topoisomerase II results reinforced the link between the cytotoxicity and topoisomerase II inhibition. Surprisingly, despite its lower cytotoxicity, the 11-chloro derivative **4c** showed the highest topoisomerase II activity with an MIC value of 0.25 μM . When analysing its drug uptake profile, the percentage drug uptake was lower than both the 11-butylamino derivative **3b** and parent cryptolepine **1**, reaching an intracellular concentration of only 25% in the first 30 minutes. In contrast to this despite its lower topoisomerase II activity, 11-iodocryptolepine **4b** (MIC = 0.5 μM) gave a higher cytotoxicity value compared to the 11-chlorocryptolepine.

Fluorescence microscopic images showed that, although **3b** was dispersed throughout the cell, high concentrations were localised in the nucleus. Despite this also being observed in 11-chlorocryptolepine **4c**, the amount of drug localised in the nucleus is dramatically lower than for **3b**. This indicates not only that a smaller amount of the **4c** is being taken up by the cells but also that it is not reaching the nucleus effectively. We have also shown that 5-ethyl cryptolepines (**3e** & **4d**) have substantially lower anti-cancer activity than 5-methyl derivatives and make unlikely lead compounds.

We report the synthesis, characterisation and *in vitro* testing of two new classes of cryptolepine derivatives and have considered their interaction with topoisomerase II and as DNA intercalators. In addition, we highlight that whilst topoisomerase II inhibition is a potentially important mode of action for cryptolepine anti-cancer activity, the direct intercalation of duplex DNA as well as cell permeability significantly influence the anti-cancer profile of any such derivative. This is important in deciding what potential anticancer motifs derivatives of this class of molecule will require to enhance activity and selectivity. Our group is currently working on the combination of halogenations and substitution of the cryptolepine with amine bearing moieties.

In conclusion, this work has shown that novel amino and halogenated cryptolepine analogues have greater *in vitro* cytotoxicity than the parent compound and are important lead compounds in the development of novel potent and selective indoloquinone anti-neoplastic agents. Further synthesis of derivatives which incorporate the amino and halogen groups may yet result in enhanced activity and potential selectivity for G-quadruplex DNA, leading to indirect telomerase inhibition, which are currently being investigated.

Acknowledgements

The authors would like to thank Kingston University for the provision of support for Venkatesh Gudivika and Dr Jean-Marie Peron for excellent support in NMR interpretation. A special thanks go to Dr Eleanor Polycarpou for proof reading and useful discussions on the biological aspects.

Notes and references

- 1 J. N. Lisgarten, M. Coll, J. Portugal, C. W. Wright and J. Aymami, *Nat. Struct. Biol.*, 2002, **9**, 57.
- 2 C. W. Wright, J. Addae-Kyereme, A. G. Breen, J. E. Brown, M. F. Cox, S. L. Croft, Y. Gokcek, H. Kendrick, R. M. Phillips and P. L. Pollet, *J. Med. Chem.*, 2001, **44**, 3187.
- 3 O. Onyeibor, S. L. Croft, H. Dodson, M. Feiz-Haddad, H. Kendrick, N. J. Millington, S. Parapini, R. M. Phillips, S. Seville, S. D. Shnyder, S. Taramelli and C. W. Wright, *J. Med. Chem.*, 2005, **48**, 2701.
- 4 L. G. Mardenborough, X. Y. Zhu, P. C. Fan, M. R. Jacob, S. I. Khan, L. A. Walker and S. Y. Ablordeppey, *Bioorg. Med. Chem.*, 2005, **13**, 3955.
- 5 S. Seville, O. Onyeibor, M. Feiz-haddad, N. Karodia, R. M. Phillips and C. W. Wright, *J. Pharm. Pharmacol.*, 2003, **55**, S.32.
- 6 P. Jerrum, C. W. Wright, A. Jewell, J. E. Brown and S. Carrington, *J. Pharm. Pharmacol.*, 2007, **59**, A2.
- 7 P. Jerrum, C. W. Wright, R. M. Phillips, S. R. Gouni, J. E. Brown and S. Carrington, *J. Pharm. Pharmacol.*, 2006, **58**, A59.
- 8 S. R. Gouni, S. Carrington and C. W. Wright, *J. Heterocycl. Chem.*, 2006, **43**, 171.
- 9 J. Lavrado, R. Moreira and A. Paulo, *Curr. Med. Chem.*, 2010, **17**, 2348.
- 10 K. Bonjean, M. C. De Pauw-Gillet, M. P. Defresne, P. Colson, C. Houssier, L. Dassonneville, C. Bailly, R. Greimers, C. Wright, J. Quetin-Leclercq, M. Tits and L. Angenot, *Biochemistry*, 1998, **37**, 5136.
- 11 L. Dassonneville, K. Bonjean, M. C. De Pauw-Gillet, P. Colson, C. Houssier, J. Quetin-Leclercq, L. Angenot and C. Bailly, *Biochemistry*, 1999, **38**, 7719.
- 12 W. Luniewski, J. Wietrzyk, J. Godlewska, M. Switalska, M. Piskozub, W. Pec-zynska-Czoch and L. Kaczmarek, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 6103.
- 13 L. Guittat, P. Alberti, F. Rosu, S. Van Miert, E. Thetiot, L. Pieters, V. Gabeli-ca, E. De Pauw, A. Ottaviani, J. F. Riou and J. L. Mergny, *Biochimie*, 2003, **85**, 535.
- 14 (a) O. A. Olajide, E. H. Heiss, D. Schachner, C. W. Wright, A. M. Vollmar and V. M. Dirsch, *Bioorg. Med. Chem.*, 2007, **15**, 43–49; (b) D. Laryea, A. Isaksson, C. W. Wright, R. Larsson and P. Nygren, *Invest. New Drugs*, 2009, **27**, 402–411; (c) H. Zhu and N. J. Gooderham, *Toxicol. Sci.*, 2006, **91**, 132–139.



- 15 Y. Gokcek, P. Pollet, C. W. Wright and J. E. Brown, *J. Pharm. Pharmacol.*, 2000, **52**, 109.
- 16 C. Avendaño and J. C. Menendez, *Medicinal chemistry of anticancer drugs*, Elsevier, 2008.
- 17 D. S. Alberts, Y. M. Peng, G. T. Bowden, W. S. Dalton and C. Mackel, *Invest. New Drugs*, 1985, **3**, 101.
- 18 (a) D. D. Von Hoff, C. A. Coltman and B. Forseth, *Cancer Res.*, 1981, **41**, 1853; (b) M. Sarwar, D. Ajami, G. Theodorakopoulos, I. Petsalakis and J. Rebek Jr., *J. Am. Chem. Soc.*, 2013, **135**, 13672.
- 19 T. Li, Z. Zeng, V. A. Estevez, K. U. Baldenius, K. Nicolaou and G. F. Joyce, *J. Am. Chem. Soc.*, 1994, **116**, 3709.
- 20 L. Dassonneville, A. Lansiaux, A. Wattelet, N. Wattez, C. Mahieu, S. Van Miert, L. Pieters and C. Bailly, *Eur. J. Pharmacol.*, 2000, **409**, 9.
- 21 C. Bailly, W. Laine, B. Baldeyrou, M. C. De Pauw-Gillet, P. Colson, C. Houssier, K. Cimanga, S. Van Miert, A. J. Vlietinck and L. Pieters, *Anti-Cancer Drug Des.*, 2000, **15**, 191.
- 22 A. M. Burger, T. C. Jenkins, J. A. Double and M. C. Bibby, *Br. J. Cancer*, 1999, **81**, 367.
- 23 C. Molenaar, J. Teuben, R. J. Heetebrij, H. J. Tanke and J. Reedijk, *J. Biol. Inorg. Chem.*, 2000, **5**, 655.
- 24 C. Redshaw, M. R. Elsegood, J. W. Frese, S. Ashby, Y. Chao and A. Mueller, *Chem. Commun.*, 2012, **48**, 6627.
- 25 M. Cheng, Y. Yang, Y. Wong, T. Chen, C. Lee, C. Yang, S. Chen, I. Yang, Y. Yang, H. Huang, C. Yang, M. Huang and H. Chiu, *Anti-Cancer Drugs*, 2012, **23**, 191.
- 26 A. Kunwar, A. Barik, B. Mishra, K. Rathinasamy, R. Pandey and K. I. Priyadarsini, *Biochim. Biophys. Acta*, 2008, **1780**, 673.
- 27 D. Monchaud, C. Allain, H. Bertrand, N. Smargiasso, F. Rosu, V. Gabelica, A. De Cian, J. Mergny and M. Teulade-Fichou, *Biochimie*, 2008, **90**, 1207.

